Skip to main content
    A

    Armata Pharmaceuticals Inc (ARMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $2.78
    -0.32 (-10.32%)

    Market Cap: $103.37M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(22/38)
    Avg Surprise
    -19.67%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.56
    Range$-0.57 - $-0.54
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.39-42.3%
    60d ago$-0.39-42.3%
    30d ago$-0.57+2.6%
    7d ago$-0.560.0%
    Current$-0.56
    Revenue Consensus
    $450000
    Range$0 - $900000
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.48
    Range$-0.89 - $-0.08
    2 analysts
    Revenue Consensus
    $3M
    Range$2M - $4M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.48---
    Sep 26EST
    		-$-0.56---
    Jun 26
    Reported Aug 12
    		$-0.27$-0.48+43.75%Beat+6.9%
    Mar 26
    Reported May 13
    		$-3.16$-0.38-731.58%Miss-1480.0%
    Dec 25
    Reported Mar 25
    		$-0.51$-0.19-169.05%Miss-120.6%
    Sep 25
    Reported Nov 12
    		$-0.33$-0.42+21.43%Beat-120.0%
    Jun 25
    Reported Aug 12
    		$-0.29$-0.39+25.64%Beat+27.5%
    Mar 25
    Reported May 14
    		$-0.20$-0.38+47.37%Beat+39.4%
    Dec 24
    Reported Mar 20
    		$-0.23$-0.35+33.80%Beat+57.9%
    Sep 24
    Reported Nov 13
    		$-0.15$-0.28+46.43%Beat+53.1%
    Jun 24
    Reported Aug 13
    		$-0.40$-0.36-11.11%Miss-48.1%
    Mar 24
    Reported May 7
    		$-0.33$-0.31-6.45%Miss-6.5%
    Dec 23
    Reported Mar 21
    		$-0.55$-0.35-57.14%Miss-89.7%
    Sep 23
    Reported Nov 14
    		$-0.32$-0.31-3.23%Miss-33.3%
    Jun 23
    Reported Aug 14
    		$-0.27$-0.37+27.03%Beat-3.8%
    Mar 23
    Reported May 11
    		$-0.31$-0.32+3.13%Beat-3.3%
    Dec 22
    Reported Mar 16
    		$-0.29$-0.28-3.57%Miss-26.1%
    Sep 22
    Reported Nov 9
    		$-0.24$-0.28+14.29%Beat+4.0%
    Jun 22
    Reported Aug 11
    		$-0.26$-0.23-13.04%Miss-4.0%
    Mar 22
    Reported May 12
    		$-0.30$-0.21-42.86%Miss-11.1%
    Dec 21
    Reported Mar 17
    		$-0.23$-0.28+17.86%Beat+36.1%
    Sep 21
    Reported Nov 10
    		$-0.25$-0.26+3.85%Beat+19.4%
    Jun 21
    Reported Aug 12
    		$-0.25$-0.26+3.85%Beat+3.8%
    Mar 21
    Reported May 13
    		$-0.27$-0.32+15.63%Beat+44.9%
    Dec 20
    Reported Mar 18
    		$-0.36$-0.29-24.14%Miss+25.0%
    Sep 20
    Reported Nov 12
    		$-0.31$-0.25-24.00%Miss+57.5%
    Jun 20
    Reported Aug 13
    		$-0.26$-0.35+25.71%Beat+53.6%
    Mar 20
    Reported May 14
    		$-0.49$-0.31-58.06%Miss+68.2%
    Dec 19
    Reported Mar 19
    		$-0.48$-0.72+33.33%Beat+77.1%
    Sep 19
    Reported Nov 12
    		$-0.73$-0.45-62.22%Miss+47.9%
    Jun 19
    Reported Aug 14
    		$-0.56$-0.36-55.56%Miss+78.9%
    Mar 19
    Reported May 6
    		$-1.54$-1.54+0.00%Beat+54.2%
    Dec 18
    Reported Mar 25
    		$-2.10$-0.98-114.29%Miss+40.0%
    Sep 18
    Reported Nov 8
    		$-1.40$-1.40+0.00%Beat-11.1%
    Jun 18
    Reported Aug 9
    		$-2.66$-2.80+5.00%Beat-119.8%
    Mar 18
    Reported May 15
    		$-3.36$-2.66-26.32%Miss+87.6%
    Dec 17
    Reported Mar 14
    		$-3.50$-5.04+30.56%Beat-933.3%
    Sep 17
    Reported Nov 14
    		$-1.26N/A+79.07%Beat-
    Jun 17
    Reported Aug 14
    		$-1.21N/AN/ABeat-
    Mar 17
    Reported May 15
    		$-27.16N/A+76.34%Beat-
    Dec 16
    Reported Mar 27
    		$0.42N/A+101.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.65EV/EBITDAN/A
    Price/FCF-3.96xFCF Yield-25.25%
    Profitability
    Profit Margin0.00%Operating Margin-410.80%
    ROE-3439.00%ROIC601.39%
    Financial Health
    Debt/Equity-0.89xInterest CoverageN/A
    Current Ratio0.11xQuick Ratio0.11x
    Trading Statistics
    Beta1.41Avg Volume157.40K
    52-Week High$16.3452-Week Low$2.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.52
    SMA 20$3.70
    SMA 50$4.49
    SMA 200$7.21
    EMA 10$3.47
    EMA 20$3.77
    EMA 50$4.42
    EMA 200$5.84

    MACD

    Line: -0.39Signal: -0.35Hist: -0.04

    ADX

    ADX: 11.9+DI: 15.0-DI: 29.6

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down100.0
    PSAR$3.72

    Bollinger Bands

    Upper Band$4.41
    Lower Band$2.98
    %B Position3884%(Upper)
    Band Width-0.14

    RSI (14-Day)

    Oversold
    28.6

    Momentum Oscillators

    Stoch %K15.1
    Stoch %D24.7
    Williams %R-97.4
    ROC (10d)-24.3%
    Momentum-0.89
    CCI (20d)-245.4
    MFI (14d)51.3

    Volatility Measures

    ATR (14d)$0.41(14.7%)
    StdDev (20d)0.36
    Hist Vol97.0%(High)

    Volume Flow

    VWAP$2.86
    OBV28.6M
    AD Line-272.0K
    CMF (20d)-0.317

    Volume Metrics

    Avg Vol (20d)125.3K
    Vol Ratio1.0x
    VWMA (20d)$3.69

    Pivot Points

    R3$4.19
    R2$3.93
    R1$3.52
    Pivot Point$3.26
    S1$2.85
    S2$2.59
    S3$2.18

    Advanced Oscillators

    TSI-27.11
    Ultimate Osc32.8
    KST-262.45

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.51M$789,000$1.08M$1.16M$2.17M$491,000$1.24M$2.97M$0$966,000$1.53M$1.23M
    Cost of Revenue$0$0$418,000$0$0$0$380,000$0$0$0$293,000$0
    Gross Profit$2.51M$789,000$1.08M$1.16M$2.17M$491,000$1.24M$2.97M$0$966,000$1.53M$1.23M
    Operating Expenses$12.82M$9.57M$14.91M$8.94M$9.01M$8.68M$11.77M$12.73M$11.91M$11.19M$11.11M$11.56M
    R&D$7.59M$6.11M$6.07M$5.82M$6.39M$5.43M$8.45M$9.48M$8.47M$8.02M$7.93M$7.98M
    SG&A$5.24M$3.46M$3.43M$3.11M$2.62M$3.25M$3.32M$3.24M$3.44M$3.18M$3.18M$3.58M
    Operating Income$-10,312,000$-8,785,000$-13,823,000$-7,776,000$-6,844,000$-8,191,000$-10,538,000$-9,756,000$-11,914,000$-10,228,000$-9,579,000$-10,336,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$106.56M$110.47M$0$9.45M$0$-2,166,000$0$0$0$10.27M$3.86M
    Income Before Tax$74.14M$-115,346,000$-124,298,000$-26,675,000$-16,295,000$-6,531,000$2.60M$-5,481,000$8.99M$-25,021,000$-19,847,000$-31,161,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$74.14M$-115,346,000$-124,298,000$-26,675,000$-16,295,000$-6,531,000$2.60M$-5,481,000$8.99M$-25,021,000$-19,847,000$-31,161,000
    EBITDA$74.73M$-114,889,000$-123,880,000$-26,305,000$-15,929,000$-6,154,000$814,000$-5,168,000$9.30M$-24,704,000$-19,490,000$-27,077,000
    EBIT$74.14M$-115,346,000$-124,298,000$-26,675,000$-16,295,000$-6,531,000$434,000$-5,481,000$8.99M$-25,021,000$-19,783,000$-27,298,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARMP

    News

    H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15

    H.C. Wainwright has reiterated its Buy rating for Armata Pharmaceuticals (ARMP.US) and maintained its target price at $15. This indicates a continued positive outlook from the analyst firm regarding the company's stock...

    Moomoo•10/10/26•Bullish

    Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

    Armata Pharmaceuticals announced the issuance of two new U.S. patents for its bacteriophage programs, AP-SA02 and AP-PA02...

    PR Newswire•10/7/26•Bullish

    Armata Pharmaceuticals receives two U.S. patents for phage therapies

    Armata Pharmaceuticals announced it has received two U.S. patents for its bacteriophage clinical candidates, AP-SA02 and AP-PA02. These patents strengthen the company's intellectual property in treating Staphylococcus...

    StreetInsider•10/7/26•Bullish

    Two patents protect experimental therapies for bacterial infections into the 2040s

    Armata Pharmaceuticals announced the issuance of two U.S. patents protecting its clinical bacteriophage candidates, AP-SA02 and AP-PA02...

    Stock Titan•10/7/26•Somewhat-Bullish

    Armata Pharmaceuticals Inc (ARMP-A) Stock Price and News

    This article provides detailed stock information for Armata Pharmaceuticals Inc. (ARMP-A), including real-time quotes, price movements...

    The Globe and Mail•10/1/26•Bullish

    ARMP Valuation and Fair Value

    P/E
    -0.7x
    P/FCF
    -4.0x
    P/B
    -0.4x
    See GNG's fair value

    ARMP Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -410.8%
    Net margin
    0.0%
    ROIC
    601.4%
    ROE
    -3439.0%
    FCF margin
    -465.3%
    FCF yield
    -25.2%

    ARMP Competitors

    CompanyTicker
    Vivani Medical Inc.VANI
    PDS Biotechnology CorpPDSB
    Definitive Healthcare CorpDH
    Unicycive Therapeutics IncUNCY
    Genelux Corporation Common StockGNLX
    Inovio Pharmaceuticals IncINO
    Stereotaxis IncSTXS
    Corbus Pharmaceuticals HoldingCRBP

    Sector: Healthcare

    ARMP Bull Case vs Bear Case

    Bull case

    • ARMP earns a 601.4% return on invested capital.
    • ARMP beat EPS estimates in 75.0% of its last 8 reported quarters.
    • ARMP grew quarterly revenue 15.7% year over year.

    ARMP Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    -85.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.56
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About ARMP

    Does ARMP pay dividends?

    Armata Pharmaceuticals Inc (ARMP) does not currently pay a regular dividend.

    What is ARMP's market cap?

    Armata Pharmaceuticals Inc (ARMP) has a market capitalization of $103.37M with a current stock price of $2.78.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In